Jayastu Senapati, MBBS
Department of Leukemia, Division of Cancer Medicine
About Dr. Jayastu Senapati
Dr. Senapati is an Assistant Professor in the Dept of Leukemia at the University of Texas MD Anderson Cancer Center, Houston Texas. He graduated from the Christian Medical College at Vellore in India followed by further residency in Internal Medicine in the same institution followed by Clinical Hematology fellowship at AIIMS, New Delhi. He subsequently did a leukemia fellowship at MD Anderson Cancer Center and joined the department as faculty. Dr. Senapati treats patients with acute and chronic leukemias and focuses on management of critical acute leukemia patients. He believes in patient centric leukemia care, that is driven by the latest research and evidence-based medicine. His research focus is primarily on acute myeloid leukemia and acute lymphoblastic leukemia, and he has been involved in several clinical trials and research projects. He has important publications on leukemia therapy and management in high-impact journals like Lancet Haematology, Journal of Clinical Oncology, Blood, Leukemia, Clinical Cancer Research, Blood Cancer Journal, Cancer, Haematologica amongst others. He has presented several important data in national and international conferences like American Society of Hematology, American Society of Clinical Oncology and European Hematology Association annual meetings. During his medical training, residency, and fellowships he has received several awards including a coveted National Scholarship by the Govt. of India, S.C. Devadutta Award in Biochemistry, Paul Harrison Award in Neurology, J.C.M. Shastry Award in nephrology, P.H. Chandrashekhar Gold Medal in Infections Diseases, Mammen Chandy Gold Medal in Hematology, Post Graduate Gold Medal in Rheumatology, M.S Seshadri Award in Endocrinology, amongst others. During his leukemia fellowship at MD Anderson Cancer Center, he received the Best Leukemia Research Fellow of the Year Award and Best Leukemia Clinical Fellow of the Year Award in successive years. Dr. Senapati works with a team of well-trained and empathetic nurses and mid-level providers whose primary focus is to offer the best treatment approach for their patients and holistic care.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
AML- Acute Myeloid Leukemia
ALL- Acute Lymphoblastic Leukemia
MPAL- Mixed Phenotypic Acute Leukemia
Clinical Interests
AML- Acute Myeloid Leukemia
ALL- Acute Lymphoblastic Leukemia
MPAL- Mixed Phenotypic Acute Leukemia
CML- Chronic Myeloid Leukemia
CLL- Chronic Lymphocytic Leukemia
AA- Aplastic Anemia
Education & Training
Degree-Granting Education
| 2012 | Christian Medical College and Hospital, Vellore, Tamil Nadu, IN, Medicine, MBBS |
Postgraduate Training
| 2021-2023 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2018-2021 | Clinical Fellowship, D. M. Clinical Hematology, All India Institute of Medical Sciences, New Delhi |
| 2015-2018 | Clinical Residency, Internal Medicine, Christian Medical College, Vellore |
Licenses & Certifications
| 2023 | Texas Medical Board |
| 2023 | Faculty Temporary License |
Experience & Service
Faculty Academic Appointments
Fellow, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Senior Resident, Department of Clinical Haematology, All India Institute of Medical Sciences, New Delhi, 2018 - 2021
Resident, Department of Internal Medicine, Christian Medical College, Vellore, 2018 - 2021
Clinical Assistant, Department of Medical Intensive Care Unit, Christian Medical College, Vellore, 2014 - 2015
Clinical Assistant, Department of Clinical Hematology, Christian Medical College, Vellore, 2013 - 2014
Internship, Christian Medical College, Vellore, 2012 - 2013
Administrative Appointments/Responsibilities
Advisor, Department of Resident Doctor's Association, All India Institute of Medical Sciences, New Delhi, 2021 - 2021
Resident's Batch Representative, Department of Internal Medicine, Christian Medical College, Vellore, 2018 - 2021
Honors & Awards
| 2023 | ASH Abstract Achievement Award, American Society of Hematology |
| 2023 | Alumni Recognition and Gratitude Award, St. Xavier's School, Durgapur, West Bengal, India |
| 2022 | ASH Abstract Achievement Award, American Society of Hematology |
| 2022 | Leukemia Clinical Fellow of the Year, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston |
| 2022 | Leukemia Research Fellow of the Year, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston |
| 2022 | EHA Congress Travel Award, European Hematology Association |
| 2022 - 2023 | ASCO Conquer Cancer Merit Award, American Society of Clinical Oncology |
| 2021 | COVID-19 Warrior Award for Exceptional Care to patients during the COVID-19 pandemic, Resident Doctor's Association, All India Institute of Medical Sciences, New Delhi, India |
| 2020 | First Place in Malignant Hematology Quiz at RGCON, Rajiv Gandhi Cancer Institute and Research Centre |
| 2020 | Second Place in National Round of Indian Myeloma Congress Quiz, Indian Myeloma Academic Groupe |
| 2017 | First Place in National Hematology Quiz, Indian Society of Hematology and Transfusion Medicine |
| 2017 | Post Graduate Gold Medal in Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Christian Medical College and Hospital, Vellore, India |
| 2016 | Best Oral Paper in Malignant Clinical Hematology, Hematocon 2016, Indian Society of Hematology and Transfusion Medicine |
| 2016 | M. S. Seshadri Prize in Endocrinology for postgraduate residents in MD Medicine/Pediatrics, Department of Endocrinology, Christian Medical College and Hospital, Vellore, India |
| 2016 | Post Graduate Gold Medal in Hematology, Department of Hematology, Christian Medical College and Hospital, Vellore, India |
| 2016 | First Place in State and Zonal Round of Indian Rheumatology Association Quiz, Indian Rheumatology Association |
| 2015 | First Place in National Hematology Quiz, Indian Society of Hematology and Transfusion Medicine |
| 2015 | P.H. Chandrasekhar Post Graduate Gold Medal in Infectious Disease, Department of Infectious Disease, Christian Medical College and Hospital, Vellore |
| 2015 | First Place in Clinical Infectious Disease Society of India National Quiz, Clinical Infectious Disease Society of India |
| 2011 | National Refresher Course in Pediatrics Quiz, Sri Ramachandra Medical College and Hospital, Chennai |
| 2011 | J.C.M. Shastry, Department of Nephrology, Christian Medical College and Hospital, Vellore, India |
| 2011 | Indian Academy of Pediatrics Quiz for Undergraduate Medical Students, Indian Academy of Pediatrics |
| 2011 | Captain JaiSingh Jadhav Prize in Pediatrics, Department of Child Health, Christian Medical College and Hospital, Vellore, India |
| 2010 | S. C. Devadutta Prize in Biochemistry, Department of Biochemistry, Christian Medical College and Hospital, Vellore, India |
| 2010 | Undergraduate Endocrinology Quiz, Department of Endocrinology, Christian Medical College and Hospital, Vellore, India |
| 2010 | Fujio Cup Quiz on Stem Cells and Regenerative Medicine, Nichi-in Center for Regenerative Medicine, India |
| 2009 | Paul Harrison Award in Neurology, Department of Neurology, Christian Medical College and Hospital, Vellore, India |
| 2005 | National talent Search Examination Scholar, National Council of Education Research and Training, Govt. of India |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2020. Management of CLL in 2020. Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2020. Treatment of smoldering multiple myeloma improves outcomes (Motion: For). Invited. Departmental Monthly Debate Series. New Delhi, Delhi, IN.
- 2020. Langerhans cell histiocytosis and Rosai Dorfman disease, from bench to bedside (Clinical aspect). Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2020. Antimicrobial prophylaxis and therapy in acute leukemia. Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2020. New advances in the treatment of pediatric lymphoma. Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2020. TP53 mutated AML: exploring treatment options. Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2019. Approach to patients with inhibitors in hemophilia: Treating acute bleeds. Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2018. Update on Auto-Immune lymphoproliferative syndrome. Invited. Hematology Weekly Seminar. New Delhi, Delhi, IN.
- 2018. Acute megakaryoblastic leukemia: clinicopathological correlation. Invited. Hematology Clinical Meet. New Delhi, Delhi, IN.
Regional Presentations
- 2022. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)– Based Regimen. Clinical Lymphoma Myeloma and Leukemia. Conference. MD Anderson Cancer Center. Houston, US.
- 2021. Imatinib dose escalation in CML: indications, response and outcomes- Thesis in support of DM degree in Clinical Haematology. Conference. All India Institute of Medical Science. New Delhi, IN.
- 2019. ADAMTS13 levels and von Willebrand Factor (vWF) collagen activity in dengue fever (AVID study). Conference. International academy of clinical haematology (IACH). Paris, US.
- 2018. Hematology case discussion at Delhi Hematology Group quarterly conference. Conference. Delhi Hematology Group. New Delhi, IN.
- 2016. Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience. Conference. Hematocon (Indian Society of Hematology and Blood Transfusion) Bengaluru. Bengaluru, US.
National Presentations
- 2023. Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance. Blood. Invited. American Society of Hematology, US.
- 2023. Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis. Blood. Invited. American Society of Hematology, US.
- 2023. Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy. Blood. Invited. American Society of Hematology, US.
- 2023. Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL). Blood. Invited. American Society of Hematology, US.
- 2023. P585: Impact Of Myeloid Mutation Profile On PCR Responses And Survival In Patients With Core-Binding Factor Aml Treated With Flag Based Regimes. Hemasphere. Conference. European Hematology Association, US.
- 2023. A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). Conference. Journal of Clinical Oncology, US.
- 2023. Poster presentation at the European Hematology Association. Conference. Poster presentation at the European Hematology Association, US.
- 2023. Poster and Oral presentation at the American Society of Hematology. Conference. Poster and Oral presentation at the American Society of Hematology, US.
- 2023. Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses. Blood. Conference. American Society of Hematology, US.
- 2023. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. Blood. Conference. American Society of Hematology, US.
- 2022. Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood. Conference. American Society of Hematology, US.
- 2022. Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood. Conference. American Society of Hematology, US.
- 2022. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML). Blood. Conference. American Society of Hematology, US.
- 2022. Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy. Blood. Conference. American Society of Hematology, US.
- 2022. Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia. Blood. Conference. American Society of Hematology, US.
- 2022. Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia. Blood. Conference. American Society of Hematology, US.
- 2022. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. Blood. Invited. American Society of Hematology, US.
- 2022. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood. Invited. American Society of Hematology, US.
- 2022. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood. Invited. American Society of Hematology, US.
- 2022. Poster presentation at the European Hematology Association. Conference. Poster presentation at the European Hematology Association, US.
- 2022. Poster presentation at the Society of Hematologic Oncology. Conference. Poster presentation at the Society of Hematologic Oncology. Houston, US.
- 2022. Poster and Oral presentation at the American Society of Hematology. Conference. Poster and Oral presentation at the American Society of Hematology, US.
- 2022. A phase II study of Inotuzumab Ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia. HemaSphere. Conference. European Hematology Association, US.
- 2022. Impact of molecular response and chemotherapy regimen on outcomes in core binding factor AML. HemaSphere. Invited. European Hematology Association, US.
- 2022. A phase I/II study of milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. HemaSphere. Conference. European Hematology Association, US.
- 2022. Impact of SF3B1 mutation in myelofibrosis. HemaSphere. Conference. European Hematology Association, US.
- 2022. A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. HemaSphere. Invited. European Hematology Association, US.
- 2022. Long-term outcomes of newly diagnosed CRLF2 rearranged B-cell ALL. Journal of Clinical Oncology. Invited. American Society of Clinical Onoclogy, US.
- 2016. Oral presentation at Hematocon (Indian Society of hematology and blood transfusion annual meet), Bengaluru. Conference. Oral presentation at Hematocon (Indian Society of hematology and blood transfusion annual meet), Bengaluru. Bengaluru, US.
International Presentations
- 2025. Advances in CART cell therapy in adult ALL. Invited. Kolkata, IN.
- 2025. What's new in AML in 2025. Invited. New Delhi, IN.
- 2025. Updates in Secondary and TP53 mutated AML. Invited. Dept. of Hematology. Kolkata, IN.
- 2023. Treatment of Older Adults with B-cell Acute Lymphoblastic Leukemia. Invited. ALL Research and Care Network (ALRCaN) Webinar, US.
- 2023. Superior outcomes after allogeneic stem cell transplantation among patients ≥ 60 years treated with cladribine, low dose cytarabine plus venetoclax for newly diagnosed acute myeloid leukemia (AML). Poster. American Society of Clinical Oncology Annual Meeting, US.
- 2023. Impact Of Myeloid Mutation Profile On PCR Responses And Survival In Patients With Core-Binding Factor Aml Treated With Flag Based Regimes. Poster. European Hematology Association Annual Meeting. Franfurt, DE.
- 2023. A phase 2 study of the combination of decitabine, venetoclax, and ponatinib in patients with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). Poster. American Society of Clinical Oncology Annual Meeting, US.
- 2022. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia. Conference. American Society of Hematology Meeting. Louisiana, US.
- 2022. Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy. Poster. American Society of Hematology Annual Meeting, US.
- 2022. Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Poster. American Society of Hematology Annual Meeting, US.
- 2022. Phase I/II Study of Azacitidine with Venetoclax and Magrolimab in Patients with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory AML. Conference. American Society of Hematology Annual Meeting, US.
- 2022. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Poster. American Society of Hematology Annual Meeting, US.
- 2022. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Poster. American Society of Hematology Annual Meeting, US.
- 2022. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia. Poster. American Society of Hematology Annual Meeting, US.
- 2022. Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia. Poster. American Society of Hematology Annual Meeting. Louisiana, US.
- 2022. Predictors of Veno-Occlusive Disease of the Liver in Patients Treated with Inotuzumab Ozogamicin ) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia. Poster. American Society of Hematology Annual Meeting, US.
- 2022. ASCO CLL Clinical Congress. Invited. ASCO CLL Clinical Congress. Chicago, US.
- 2022. A phase I/II study of milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. Poster. European Hematology Association Annual Meeting. Venice, AT.
- 2022. A phase II study of Inotuzumab Ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia. Poster. European Hematology Association Annual Meeting. Venice, AT.
- 2022. Impact of molecular response and chemotherapy regimen on outcomes in core binding factor AML. Poster. European Hematology Association Annual Meeting. Venice, AT.
- 2022. Impact of SF3B1 mutation in myelofibrosis. Poster. European Hematology Association Annual Meeting. Venice, AT.
- 2022. A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Poster. European Hematology Association Annual Meeting. Venice, AT.
- 2022. Long-term outcomes of newly diagnosed CRLF2 rearranged B-cell ALL. Poster. American Society of Clinical Oncology Annual Meeting, US.
Formal Peers
- 2024. Optimal use of Azacitidine and Ventoclax in AML. Invited, IN.
Selected Publications
Peer-Reviewed Articles
- Short, NJ, Kantarjian, HM, Furudate, K, Jain, N, Ravandi-Kashani, F, Karrar, OS, Loghavi, S, Nasr, L, Haddad, FG, Senapati, J, Garris, R, Takahashi, K, Jabbour, EJ. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 40369607.
- Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, Kadia, TM, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
- Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, Kadia, TM, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
- Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Gangat, N, Elbeih, A, Ghosoun, N, McCullough, K, Aperna, F, Johnson, IM, Abdelmagid, M, Al-Kali, A, Alkhateeb, HB, Begna, K, Elliott, MA, Mangaonkar, AA, Matin, A, Saliba, AN, Hefazi Torghabeh, M, Litzow, M, Hogan, WJ, Shah, MV, Patnaik, MM, Pardanani, A, Badar, T, Murthy, H, Foran, J, Palmer, J, Sproat, L, Khera, N, Arana Yi, C, Yates, S, Sneider, A, Dworkin, E, Patel, A, Bazinet, A, Senapati, J, Bataller Torralba, A, DiNardo, C, Kadia, TM, Tefferi, A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. American journal of hematology 100(2):260-271, 2025. e-Pub 2025. PMID: 39671248.
- Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation. Am J Hematol 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, Ferrajoli A, Sasaki K, Alvarado Y, Pemmaraju N, Senapati J, Garris R, Ravandi F, Jabbour E. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol, 2025. e-Pub 2025. PMID: 39757533.
- Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica, 2024. e-Pub 2024. PMID: 39665206.
- Haddad, FG, Sasaki, K, Senapati, J, Xiao, L, Park, GS, Abuasab, T, Venugopal, S, Rivera, D, Bazinet, A, Babakhanlou, R, Kim, K, Ong, F, Desikan, SP, Pemmaraju, N, Loghavi, S, Borthakur, G, DiNardo, C, Abbas, HA, Short, NJ, Daver, N, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis. JCO Oncology Practice 20(12):1637-1644, 2024. e-Pub 2024. PMID: 39013130.
- Haddad FG, Sasaki K, Senapati J, Hu S, Dellasala S, Issa GC, Jabbour E, Kantarjian H. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clin Lymphoma Myeloma Leuk 25(4):254-257, 2024. e-Pub 2024. PMID: 39592322.
- Short, NJ, Nguyen, D, Jabbour, EJ, Senapati, J, Zeng, Z, Issa, GC, Abbas, HA, Nasnas, C, Qiao, W, Huang, X, Borthakur, G, Chien, KS, Haddad, FG, Pemmaraju, N, Karrar, OS, Nguyen, D, Konopleva, M, Kantarjian, HM, Ravandi, F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia. The Lancet Haematology 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
- Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk 24(10):732-735, 2024. e-Pub 2024. PMID: 38945779.
- Zhang H, Raymundo JR, Daly KE, Zhu W, Senapati B, Zhong H, Ahilan AR, Marneros AG. AP-2α/AP-2β Transcription Factors Are Key Regulators of Epidermal Homeostasis. J Invest Dermatol 144(7):1505-1521.e12, 2024. e-Pub 2024. PMID: 38237728.
- Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
- Adhikari S, Singh V, Nandi S, Ghosal M, Raj NS, Khanna J, Bhattacharya A, Kabiraj A, Mondal A, Vasudevan M, Senapati D, Roy H, Sengupta K, Notani D, Das C. UBR7 in concert with EZH2 inhibits the TGF-β signaling leading to extracellular matrix remodeling. Cell Rep 43(7):114394. e-Pub 2024. PMID: 38923455.
- Gupta P, Kayal S, Tanimura N, Pothapragada SP, Senapati HK, Devendran P, Fujita Y, Bi D, Das T. Mechanical imbalance between normal and transformed cells drives epithelial homeostasis through cell competition. bioRxiv, 2024. e-Pub 2024. PMID: 37961252.
- Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol 42(17):2071-2079, 2024. e-Pub 2024. PMID: 38552193.
- Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5. e-Pub 2024. PMID: 38856690.
- Senapati PK, Kariali E, Kisan K, Sahu BB, Naik AKD, Panda D, Tripathy SK, Mohapatra S, Mohapatra PK. Comprehensive studies reveal physiological and genetic diversity in traditional rice cultivars for UV-B sensitivity. Sci Rep 14(1):13137, 2024. e-Pub 2024. PMID: 38849505.
- Lau LMS, Khuong-Quang DA, Mayoh C, Wong M, Barahona P, Ajuyah P, Senapati A, Nagabushan S, Sherstyuk A, Altekoester AK, Fuentes-Bolanos NA, Yeung V, Sullivan A, Omer N, Diamond Y, Jessop S, Battaglia L, Zhukova N, Cui L, Lin A, Gifford AJ, Fleuren EDG, Dalla-Pozza L, Moore AS, Khaw SL, Eisenstat DD, Gottardo NG, Wood PJ, Tapp H, Alvaro F, McCowage G, Nicholls W, Hansford JR, Manoharan N, Kotecha RS, Mateos MK, Lock RB, Tyrrell V, Haber M, Trahair TN, Cowley MJ, Ekert PG, Marshall GM, Ziegler DS. Precision-guided treatment in high-risk pediatric cancers. Nat Med. e-Pub 2024. PMID: 38844796.
- Maniya NH, Kumar S, Franklin JL, Higginbotham JN, Scott AM, Gan HK, Coffey RJ, Senapati S, Chang HC. An anion exchange membrane sensor detects EGFR and its activity state in plasma CD63 extracellular vesicles from patients with glioblastoma. Commun Biol 7(1):677, 2024. e-Pub 2024. PMID: 38830977.
- Acharya A, Mahapatra AK, Panigrahi S, Deo RC, Senapati SB. Pulsatile giant sacrococcygeal teratoma appearing like 2nd head. Childs Nerv Syst 40(6):1953-1956, 2024. e-Pub 2024. PMID: 38372776.
- Pani S, Senapati U, Pati B, Sahu B, Swalsingh G, Pani P, Rout S, Achary KG, Bal NC. Developmental dynamics of mitochondrial fission and fusion proteins in functionally divergent skeletal muscles of goat. Physiol Rep 12(11):e16002, 2024. e-Pub 2024. PMID: 38831632.
- Senapati SK, Pal A, Das A. Facile synthesis of tetrahydroquinoline containing dithiocarbamate derivatives via one-pot sequential multicomponent reaction. Org Biomol Chem 22(20):4041-4046, 2024. e-Pub 2024. PMID: 38700439.
- Chaves JCS, Milton LA, Stewart R, Senapati T, Rantanen LM, Wasielewska JM, Lee S, Hernández D, McInnes L, Quek H, Pébay A, Donnelly PS, White AR, Oikari LE. Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins. J Neuroimmune Pharmacol 19(1):22, 2024. e-Pub 2024. PMID: 38771543.
- Borra V, Jain A, Borra N, Kattamuri LPV, Senapati SG, Machineni NVK, Kukkala S, Ramasahayam K, Prajapati K, Vyas A, Desai R. Rising Trends in Metabolically Healthy Obesity in Cancer Patients and Its Impact on Cardiovascular Events: Insights from a Contemporary Nationwide Analysis in the USA (2016-2020). J Clin Med 13(10), 2024. e-Pub 2024. PMID: 38792362.
- Knanghat R, Senapati S. Toward Greater DNA Stability by Leveraging the Proton-Donating Ability of Protic Ionic Liquids. J Phys Chem B 128(18):4301-4314, 2024. e-Pub 2024. PMID: 38682809.
- Das S, Chandra A, Das A, Senapati S, Chatterjee G, Chatterjee R. Identifying the genetic associations among the psoriasis patients in eastern India. J Hum Genet 69(5):205-213, 2024. e-Pub 2024. PMID: 38409498.
- Sharma P, Senapati S, Goyal LD, Kaur B, Kamra P, Khetarpal P. Genome-wide association study (GWAS) identified PCOS susceptibility variants and replicates reported risk variants. Arch Gynecol Obstet 309(5):2009-2019, 2024. e-Pub 2024. PMID: 38421422.
- Panneerselvam P, Senapati A, Mitra D, Priyadarshini A, Shadangi S, Behera S, Kumar U, Kumar A, Shahid M, Sharma S, Garhwal RS, Mani I, Kumar Nayak A. Enhancing soil quality and yield through microbial assisted in-situ residue management in rice-rice cropping system in Odisha, Eastern India. J Environ Manage 358:120916, 2024. e-Pub 2024. PMID: 38642486.
- Lee MJ, Lee E, Bradburn M, Hind D, Strong EB, Din F, Wysocki AP, Lund J, Moffatt C, Morton J, Senapati A, Jones H, Brown SR, Group PM, Validators TP. Research and practice priorities in pilonidal sinus disease: a consensus from the PITSTOP study. Colorectal Dis. e-Pub 2024. PMID: 38671581.
- Barnhart KT, Bollig KJ, Senapati S, Takacs P, Robins JC, Haisenleder DJ, Beer LA, Savaris RF, Koelper NC, Speicher DW, Chittams J, Bao J, Wen Z, Feng Y, Kim M, Mumford S, Shen L, Gimotty P. Multiplexed serum biomarkers to discriminate nonviable and ectopic pregnancy. Fertil Steril. e-Pub 2024. PMID: 38677710.
- Short, NJ, Jabbour, EJ, Jain, N, Senapati, J, Nasr, L, Haddad, FG, Li, Z, Hsiao, YC, Yang, JJ, Pemmaraju, N, Ohanian, M, Wierda, WG, Montalban Bravo, G, Borthakur, G, Han, L, Xiao, L, Huang, X, Abramova, R, Zhao, M, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Advances 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
- Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
- Siab A, Sajjad Ali Khan M, Asif Jan M, Simic V, Bacanin N, Senapati T. Aczel Alsina t-norm and t-conorm-based aggregation operators under linguistic interval-valued intuitionistic fuzzy setting with application. PeerJ Comput Sci 10:e1979, 2024. e-Pub 2024. PMID: 38855242.
- Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
- Senapati J, Panda T, Rajendra A, Aggarwal M. Understanding the barriers to AML care in India. Lancet Haematol 10(9):e710-e711, 2023. e-Pub 2023. PMID: 37652600.
- Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
- Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
- Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
- Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
- Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
- Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2023. PMID: 36565294.
- Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 141(6):567-578, 2023. e-Pub 2023. PMID: 36399715.
- Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2023. PMID: 36448227.
- Sahoo PC, Senapati JR, Rana BK. Computational and Analytical Investigation of Droplet Impingement and Spreading Dynamics around the Right Circular Cone. Langmuir 38(48):14891-14908, 2022. e-Pub 2022. PMID: 36399123.
- Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):2701-2705, 2022. e-Pub 2022. PMID: 35787095.
- Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
- Rickmann AM, Senapati J, Kovalenko O, Peters A, Bamberg F, Wachinger C. AbdomenNet: deep neural network for abdominal organ segmentation in epidemiologic imaging studies. BMC Med Imaging 22(1):168, 2022. e-Pub 2022. PMID: 36115938.
- Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
- Senapati J, Devasia AJ, Korula A, Fouzia NA, Kulkarni U, Lakshmi KM, Lionel S, Abraham A, Srivastava A, Mathews V, George B. Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience. Indian J Hematol Blood Transfus 38(2):290-298, 2022. e-Pub 2022. PMID: 35496963.
- Kumar P, Aggarwal M, Dhawan R, Dass J, Kumar G, Sharma V, Mirza S, Senapati J, Ganju N, Vaid T, Vijayran M, Panda T, Pragna GS, Krishna SS, Khandelwal A, Verghese R, Tyagi S, Seth T, Mahapatra M. Tele-Medicine Services in Hematological Practice During Covid Pandemic: Its Feasibility and Difficulties. Indian J Hematol Blood Transfus 37(4):528-533, 2021. e-Pub 2021. PMID: 33250594.
- Dieckmeyer M, Roy AG, Senapati J, Wachinger C, Grundl L, Dopfert J, Bertran PF, Lemke A, Zimmer C, Kirschke JS, Hedderich DM. Effect of MRI acquisition acceleration via compressed sensing and parallel imaging on brain volumetry. MAGMA 34(4):487-497, 2021. e-Pub 2021. PMID: 33502667.
- Senapati J, Dhawan R, Aggarwal M, Kumar P, Kumar Vishwanathan G, Dass J, Tyagi S, Mahapatra M, Seth T. Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country. Leuk Lymphoma 62(6):1514-1517, 2021. e-Pub 2021. PMID: 33448885.
- Senapati J, Aggarwal M, Louis L, Mirza SA, Kumar P, Dhawan R, Dass J, Vishwanathan GK, Pandey HC, Coshic P, Tyagi S, Seth T, Mahapatra M. Transfusion practices during the COVID-19 pandemic: An experience from a hematology daycare in India. Transfus Apher Sci 60(2):103025, 2021. e-Pub 2021. PMID: 33353804.
- Senapati J, Devasia AJ, Alex AA, George B. Early T cell precursor lymphoid blast crisis of chronic myeloid leukemia - a novel transformation. Hematol Oncol Stem Cell Ther 8(1):43-6, 2015. e-Pub 2015. PMID: 25497977.
- Senapati J, Devasia AJ, David S, Manipadam MT, Nair S, Jayandharan GR, George B. Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature. Indian J Hematol Blood Transfus 30(Suppl 1):309-13, 2014. e-Pub 2014. PMID: 25332606.
- Senapati J, Devasia AJ, Sudhakar S, Viswabandya A. Asymptomatic gastrosplenic fistula in a patient with marginal zonal lymphoma transformed to diffuse large B cell lymphoma--a case report and review of literature. Ann Hematol 93(9):1599-602, 2014. e-Pub 2014. PMID: 24362455.
- Senapati J, Devasia AJ, Ganapule A, George L, Viswabandya A. Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature. Mediterr J Hematol Infect Dis 6(1):e2014016, 2014. e-Pub 2014. PMID: 24678393.
Review Articles
- Senapati, J, Kadia, TM, Daver, N, DiNardo, C, Borthakur, G, Ravandi-Kashani, F, Kantarjian, HM. Therapeutic horizon of acute myeloid leukemia. Cancer 131(7), 2025. e-Pub 2025. PMID: 40105906.
- Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ, Jabbour E. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. Leuk Lymphoma:1-12, 2025. e-Pub 2025. PMID: 39791458.
- Ray, A, Jain, A, Vijayaran, M, Thomas, S, Senapati, J, Aggarwal, M. MOVING THE NEEDLE IN KMT2A REARRANGED PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Clinical Hematology International 7(2):65-73, 2025. e-Pub 2025. PMID: 40584390.
- Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(6):333-339, 2024. e-Pub 2024. PMID: 38195323.
- Banerjee P, Senapati S. Translational Utility of Organoid Models for Biomedical Research on Gastrointestinal Diseases. Stem Cell Rev Rep. e-Pub 2024. PMID: 38758462.
- Short, NJ, Senapati, J, Jabbour, EJ. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Current hematologic malignancy reports 18(6):234-242, 2023. e-Pub 2023. PMID: 37651057.
- Senapati J, Kadia TM, Ravandi F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica 108(9):2289-2304, 2023. e-Pub 2023. PMID: 37139599.
- Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
- Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J 13(1):58, 2023. e-Pub 2023. PMID: 37088793.
- Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37(1):5-17, 2023. e-Pub 2023. PMID: 36309558.
- Senapati J, Sasaki K. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626137.
- Senapati J, Kadia TM. Which FLT3 Inhibitor for Treatment of AML?. Curr Treat Options Oncol 23(3):359-380, 2022. e-Pub 2022. PMID: 35258791.
- Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. e-Pub 2022. PMID: 36383908.
- Sahitya DSK, Jandiyal A, Jain A, Senapati J, Nanda S, Aggarwal M, Kumar P, Mohapatra S, Ray P, Malhotra P, Mahapatra M, Dhawan R. Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation. Ther Adv Infect Dis 8:20499361211053480, 2021. e-Pub 2021. PMID: 34733507.
Other Articles
- Haque, EU, Jabbour, EJ, Senapati, J, Haddad, FG Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase. Annals of Blood 9, 2024.
Editorials
- Senapati, J, Jabbour, EJ. Dar-ting at CD38 in T-cell leukemias. Blood 144(21):2162-2164, 2024. PMID: 39570597.
Book Chapters
- Senapati J. Chronic Lymphocytic Leukemia. In: Cancer Consult. 2. Wiley Blackwell, 2023.
Letters to the Editor
- Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
- Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
- Kontoyiannis, PD, Peddireddy, A, Sasaki, K, Chien, KS, Senapati, J, Montalban Bravo, G, DiNardo, C, Borthakur, G, Kanagal-Shamanna, R, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G, Urrutia, S. Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. Leukemia Research 147, 2024.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
Patient Reviews
CV information above last modified September 05, 2025